GlassScriptPhysician profile
Thad A Clements
NPI 1982676565
$2,168.25
in general payments reported to CMS, 2019-2025
27 companies · $83.75 in 2025
The $83.75 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $477 · 2021: $756 · 2022: $67.82 · 2023: $302 · 2025: $83.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $385.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $566.41 | 2019-2023 | Lokelma |
| Neurocrine Biosciences, INC. | $211.84 | 2023-2025 | Ingrezza |
| Novo Nordisk INC | $172.60 | 2020-2021 | |
| Abbvie INC. | $169.99 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.10 | 2019-2021 | |
| Astellas Pharma US INC | $104.31 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $97.03 | 2019-2021 | |
| Lilly USA, LLC | $81.28 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $68.29 | 2020-2021 | |
| Pfizer INC. | $55.04 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $48.68 | 2019 | |
| Amarin Pharma, INC. | $44.48 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.49 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $42.50 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $34.85 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Topcon Healthcare Solutions, INC. | $31.12 | 2019 | |
| Sunovion Pharmaceuticals INC. | $27.70 | 2019 | |
| Amgen INC. | $26.93 | 2020-2021 | |
| Exeltis, USA INC. | $26.80 | 2020-2021 | |
| Allergan, INC. | $24.91 | 2020 | |
| Glaxosmithkline, LLC. | $24.23 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.79 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.73 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.94 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $15.20 | 2021 | |
| Eisai INC. | $15.07 | 2021 | |
| Acadia Pharmaceuticals INC | $13.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thad Clements listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.